Genetics Division, Western Biomedical Research Center, Mexican Institute of Social Security, Guadalajara, Jalisco, México.
J BUON. 2020 Jan-Feb;25(1):176-181.
The rs712 polymorphism in a let-7 microRNA-binding KRAS gene has been associated with different types of cancer, however these associations have been inconsistent. The purpose of this study was to determine the association between rs712 polymorphism in a let-7 microRNA-binding KRAS gene comparing breast cancer (BC) patients with healthy subjects from Mexican population.
The genotyping of the rs712 polymorphism was performed by polymerase chain reaction (PCR) in 437 BC patients and 414 healthy women.
The observed frequencies of the rs712 polymorphism indicated an associated protective factor for BC in the dominant GT+TT model [odds ratio (OR) 0.70, 95% confidence interval (CI) 0.51-0.97, p=0.040). An association between genotype and BC patients was evident in chemotherapy response (allele GT, OR 0.032, 95% CI 0.002-0.505, p=0.014), partial chemotherapy response (genotype GT, OR 0.023, 95% CI 0.001-0.419, p=0.011), and gastric and hematological toxicity (genotype GT, OR 0.115, 95% CI 0.028-0.473, p=0.003), Luminal A BC patients with gastric and hematological toxicity (genotype TT, OR 0.236, 95% CI 0.069-0.805, p=0.021) and tobacco consumption (genotype TT, OR 0.283, 95% CI 0.001-0.802, p=0.037) and Luminal B with metastatic lymph node (genotype GT, OR 0.241, 95% CI 0.093-0.626, p=0.003).
Polymorphism rs712 in KRAS gene was protective factor associated with susceptibility for BC in this sample from Mexican population.
rs712 多态性位于 let-7 微RNA 结合 KRAS 基因中，与多种类型的癌症相关，但这些关联并不一致。本研究的目的是确定 rs712 多态性与墨西哥人群乳腺癌（BC）患者与健康对照之间的关系。
对 437 例 BC 患者和 414 例健康女性进行 rs712 多态性聚合酶链反应（PCR）基因分型。
rs712 多态性的观察频率表明，在显性 GT+TT 模型中，BC 的保护因子具有统计学意义[比值比（OR）0.70，95%置信区间（CI）0.51-0.97，p=0.040]。在化疗反应（等位基因 GT，OR 0.032，95%CI 0.002-0.505，p=0.014）、部分化疗反应（基因型 GT，OR 0.023，95%CI 0.001-0.419，p=0.011）、胃癌和血液学毒性（基因型 GT，OR 0.115，95%CI 0.028-0.473，p=0.003）方面，基因型与 BC 患者之间存在相关性。Luminal A 型 BC 患者中，胃癌和血液学毒性（基因型 TT，OR 0.236，95%CI 0.069-0.805，p=0.021）和烟草使用（基因型 TT，OR 0.283，95%CI 0.001-0.802，p=0.037）以及具有转移性淋巴结的 Luminal B 型（基因型 GT，OR 0.241，95%CI 0.093-0.626，p=0.003）与 rs712 多态性相关。
KRAS 基因中的 rs712 多态性是保护因子，与墨西哥人群中 BC 的易感性相关。
